Drugs / Typbar-TCV
Typbar-TCV
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03600025 | Jul 2018 → Sep 2021 | — | International Centre for Diarrhoeal Disease Research, Bangladesh | Unknown | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05475379 | Jul 2022 → Jun 2023 | typhoid fever | International Centre for Diarrhoeal Disease Research, Bangladesh | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT05771779 | Oct 2023 → May 2025 | cholera, measles, rubella, typhoid fever | International Centre for Diarrhoeal Disease Research, Bangladesh | Unknown | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT06817421 | Jan 2026 → Mar 2028 expected | pneumococcal infection, pneumonia | Nick Fancourt | Recruiting | No outcome recorded |
| Comparator or background therapy4 trials | ||||||
| Phase 1 | NCT03956524 Comparator | Mar → Aug 2019 | typhoid fever | EuBiologics Co.,Ltd | Completed | No outcome recorded |
| Phase 2 | NCT05784701 Comparator | Apr 2023 → Jan 2027 expected | — | University of Maryland, Baltimore | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT04830371 Comparator | Sep 2020 → Mar 2021 | typhoid fever | EuBiologics Co.,Ltd | Completed | Met primary |
| Phase 3 | NCT03933098 Comparator | Nov 2019 → Sep 2020 | typhoid fever | International Vaccine Institute | Unknown | Met primary |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Typbar TCV | “This study was conducted in 75 healthy adults aged 18-45 years who were randomized in a 1:1:1 ratio based on the vaccines administered: EuTCV (Test), Typbar-TCV® (WHO...” PMID 33849723 ↗ Apr 20219“Vi polysaccharide-tetanus toxoid conjugate vaccine (Vi-TCV). Trade name: Typbar-TCV®, Bharat-Biotech International Limited.” NCT05475379 ↗ “typhoid conjugate vaccine (TCV), Typbar-TCV for S. Typhi” NCT05771779 ↗ “Control Arm: Typbar TCV” NCT06817421 ↗ “Typbar TCV®” NCT03933098 ↗ |
| Known as | Vi polysaccharide-tetanus toxoid conjugate vaccine (Vi-TCV) | “Vi polysaccharide-tetanus toxoid conjugate vaccine (Vi-TCV). Trade name: Typbar-TCV®, Bharat-Biotech International Limited.” NCT05475379 ↗ |
| Known as | Vi-TCV | “Vi polysaccharide-tetanus toxoid conjugate vaccine (Vi-TCV). Trade name: Typbar-TCV®, Bharat-Biotech International Limited.” NCT05475379 ↗ |
| Modality | Vaccine | “Typbar-TCV is a Typhoid Vi capsular polysaccharide tetanus toxoid conjugate vaccine.” NCT03600025 ↗ |
| Route | Intramuscular | “vaccine will receive intramuscularly” NCT03600025 ↗ |